OraSure Targets HIV-1/2, Hepatitis Tests To Grow Business To $250 Mil.
This article was originally published in The Gray Sheet
Executive Summary
OraSure is setting its sights on obtaining FDA approval of an OraQuick HIV-2 rapid oral fluid test, as well as licensing rights from Bio-Rad for the antibody patents, following approval of an HIV-1 version March 26